Boosting anti-inflammatory potency of zafirlukast by designed polypharmacology

Simone Schierle[a]#, Cathrin Flauaus[b]#, Pascal Heitel[a], Sabine Willems[a], Jurema Schmidt[a], Astrid Kaiser[a], Lilia Weizel[a], Tamara Goebel[a], Astrid Kahnt[a], Gerd Geisslinger[c], Dieter Stein-hilber[a], Mario Wurglics[a], G. Enrico Rovati[d], Achim Schmidtko[b], Ewgenij Proschak[a]##, Daniel Merk*a][a]###

[a] Institute of Pharmaceutical Chemistry, Goethe University Frankfurt, Max-von-Laue-Str. 9, D-60438 Frankfurt, Germany
[b] Institute of Pharmacology, College of Pharmacy, Goethe University Frankfurt, Max-von-Laue-Str. 9, D-60438 Frankfurt, Germany
[c] Institute of Clinical Pharmacology, Goethe University Frankfurt, Theodor-Stern-Kai 7, D-60590 Frankfurt, Germany
[d] Institute of Pharmacological Sciences, University of Milan, Via Balzaretti 9, I-20133 Milan, Italy
* E-mail: merk@pharmchem.uni-frankfurt.de

KEYWORDS: multi-target design • drug repurposing • selective optimization of side-activities • inflammation

ABSTRACT: Multi-target design offers access to bioactive small molecules with potentially superior efficacy and safety. Particularly multifactorial chronic inflammatory diseases demand multiple pharmacological interventions for stable treatment. By minor structural changes, we have developed a close analogue of the cysteinyl-leukotriene receptor antagonist zafirlukast that simultaneously inhibits soluble epoxide hydrolase and activates peroxisome proliferator-activated receptor γ. The triple modulator exhibits robust anti-inflammatory activity in vivo and highlights the therapeutic potential of designed multi-target agents.

INTRODUCTION

Though anti-inflammatory drug discovery is very intensive,[1] inflammatory diseases remain amongst the most serious health burdens and there is unmet medical need for more efficacious anti-inflammatory drugs. The number of drugged targets in inflammatory diseases is constantly growing but especially in the most severe, chronic disorders even innovative agents fail to produce sufficient therapeutic efficacy.[2] As a very complex pathophysiological process, inflammation involves a myriad of enzymes, mediators and receptors and pharmacological modulation of a single target tends to cause shunting effects that compromise therapeutical efficacy.[3] Thus, robust anti-inflammatory therapies often require the use of multiple drugs but considering the drawbacks of excessive polypharmacy, a multi-target anti-inflammatory agent seems a superior approach.

RESULTS & DISCUSSION

To generate such multi-target anti-inflammatory agent, we selected the cysteinyl leukotriene receptor 1 (CysLT1R)[3,4] antagonist zafirlukast (1)[5] for which we have

![Figure 1. Docking analysis of the lead compound’s (1) binding mode in the PPARγ ligand binding domain (A, PDB-ID: 3WMH) and the sEH active site (B, PDB-ID: 5ALZ). Detailed views of the individual molecular building blocks and docking-derived structural modifications are shown in Figures S1&S2.](image-url)
observed moderate off-target activity (Table 1) on the peroxisome proliferator-activated receptor γ (PPARγ)⁷ and the soluble epoxide hydrolase (sEH)⁷. Like CysLT₁R, PPARγ and sEH interact with metabolites of arachidonic acid and hold great anti-inflammatory potential³ and their selective modulation reduced acute inflammation in animal models⁸,⁹. The weak side-activities of the fatty acid mimetic₁⁰ 1, therefore, seem supportive of an anti-inflammatory efficacy and we aimed to optimize the PPARγ agonistic and sEH inhibitory activity of 1 while retaining CysLT₁R antagonism to generate a triple modulator that simultaneously addresses three anti-inflammatory targets.

To establish a strategy for structural optimization, we analyzed the putative binding mode of 1 in the PPARγ ligand binding domain (PDB-ID: 3WMH) and the sEH C-terminal domain (PDB-ID: 5ALZ)¹¹ by molecular docking (Figure 1, detailed view in Figures S1&S2). Examination of the best scored poses suggested that minor changes would allow marked improvements in potency. Spatial extension of the urethane cyclopentyl substituent to a six-membered ring seemed favorable for PPARγ and sEH binding since the urethane O-substituent protruded into lipophilic sub-pockets of both targets which offered additional space for a larger ring. Moreover, caused by its ortho-methyl residue, the phenylsulfonamide obtained a dihedral conformation that was disfavored by PPARγ and might be resolved through a free ortho-position which was supported by strain energy calculations (Table S1). Interaction potential analysis in the phenylsulfonamide binding region in the PPARγ ligand binding site, furthermore, suggested opportunities for optimization in meta- or para-substitution of said ring with small halogens. And finally, replacement of the urethane moiety in 1 by urea appeared to optimize sEH inhibitory potency by adding a further H-bond donor that would enable an additional H-bond towards Asp335. Guided by these in silico observations, we prepared analogues of 1 with small but concerted structural changes to enhance triple potency.

Analogues 2-10 were prepared in an eight-step synthetic procedure adopted from a published¹² approach to 1 with suitable modifications (Scheme 1). In brief, 4-nitro-5-nitroindole (11) was available from 12 by methylation with DMS. Esterification of 13 followed by radical bromination yielded building block 14 which was coupled with 11 to 15 under Friedel-Craft conditions using FeCl₃ as catalyst. After reducing 15 with H₂ and Pd(C) to aniline 16, urethane 17 was available from 16 and chloroformate 18 while reaction of 16 with isocyanates 19 and 20 produced ureas 21 and 22. Finally, ester hydrolysis in 17, 21 and 22 to free acids 23-25 followed by sulfonamide coupling with DCC/DMAP and 26-30 afforded 2-10 in 8-12% overall yield.

PPARγ agonistic potency of analogues 2-10 was quantified in a specific reporter gene assay¹³ in HEK293T cells

Scheme 1. Synthesis of 2-10. Reagents & conditions: (a) Me₂SO₄, dioxane, 40 °C, 2.5 h; (b) MeOH, SOCl₂, reflux, 4 h; (c) CHCl₃, AlBN, NBS, reflux, 4 h; (d) FeCl₃, dioxane, reflux, 12 h; (e) H₂, Pd(C), MeOH, r.t. 12 h; (f) THF, DIPEA, C₂H₅COCl (18), 4 °C -> r.t., 4 h; (g) THF, DBU, C₆H₁₁-NCO (19) or C₆H₅-NCO (20), 40 °C, 12 h; (h) LiOH, MeOH/H₂O, r.t., 16 h; (i) CHCl₃, DCC, DMAP, R₂=Ph-SO₂NH₂ (26-30), reflux, 12 h.
based on a hybrid receptor comprising the PPARγ-LBD and the DNA-binding domain of the nuclear receptor Gal4 from yeast. Inhibition of sEH was determined in a fluorescence-based assay with recombinant protein and PHOME as fluorogenic substrate. A cellular leukotriene D4 induced Ca2+-influx assay in Cos-7 cells transiently overexpressing CysLT1;R15 served to characterize antagonistic potency of 2-10 on CysLT1;R (Table 1).

Based on our docking study, we replaced the urethane moiety of 1 by a urea (2) which was accompanied by a significant improvement in sEH inhibitory potency while CysLT1;R antagonism dropped dramatically. On PPARγ, replacement of the urethane moiety by urea hardly affected the EC50 value but significantly diminished transactivation efficacy. Considering that weight gain is a common adverse effect of full PPARγ agonists and that partial agonists lack this undesired activity while retaining anti-inflammatory effects of PPARγ modulation16-18, partial agonistic activity on PPARγ appears favorable and safer.

Ring expansion from cyclopentylurea 2 to cyclohexylurea 3 further promoted sEH inhibition and markedly improved PPARγ agonism but was poorly tolerated concerning CysLT1;R antagonism. Variations in the sulfonamide moiety were better tolerated by CysLT1;R with unsubstituted phenylsulfonamide 4 and 3-chlorophenylsulfonamide 5 retaining a pA2 value above 10. As suggested by the proposed binding mode, the freely rotatable phenylsulfonamides 4 and 5 strongly enhanced PPARγ agonistic potency. Inhibitory potency on sEH was hardly affected by changes in the sulfonamide region. Thus, we combined cyclohexylurea (3) and 3-chlorophenylsulfonamide (5) as most favorable modifications for sEH inhibition and PPARγ agonistic potency, respectively. The resulting compound 6 comprised balanced triple modulatory potency on PPARγ, sEH and CysLT1;R. Introduction of a second chlorine atom in 7 and replacement of chlorine by trifluoromethyl (8) failed to improve the triple activity while replacement of chlorine by fluorine (9) was slightly favored by PPARγ and sEH but not by CysLT1. Intriguingly, the most favorable triple activity profile was achieved with unsubstituted phenylsulfonamide 10. As assumed from the proposed binding poses, three minor structural changes were sufficient to generate a triple modulator with nanomolar potency on PPARγ, sEH and CysLT1;R.

Off-target profiling of 1 and 10 on nuclear receptors (Figure S3A) revealed significantly reduced off-target activity for the triple modulator 10 despite its designed polypharmacological profile while 1 turned out remarkably unselective. Especially its agonistic activity on pregnane X receptor (PXR) and constitutive androstane receptor (CAR) may compromise the safety of 1 since these xenobiotic receptors drive cytochrome P450 expression, promote drug metabolism and can be a basis of drug-drug interactions19,20. In contrast to 1, the triple modulator 10 was inactive on CAR and only weakly activated PXR.

Moreover, the triple modulator 10 comprised remarkably higher aqueous solubility (10: 2.1 mg/L; 1: 0.14 mg/L) and a lower logD1,4 value (10: 1.70; 1: 2.47) than 1, and was considerably less toxic (Figure S3B-D). Microsomal stability was high for both, 10 and lead structure 1 with 65% and 73%, respectively, remaining after 4 hours incubation (Figure S1E). Under cellular conditions, 10 robustly inhibited sEH product formation in HepG2 homogenates with an IC50 value of 14±2 nM and induced PPARγ target gene expression in HepG2 cells (Figure 2A/B). However, in contrast to PPARγ agonist rosiglitazone, 10 did not induce adipocyte differentiation and failed to induce PPARγ regulated gene expression in this cell-type (Figure 2C/D). Thus, 10 comprises a non-adipogenic, selective PPARγ modulatory profile as it has been observed for other PPARγ ligands18.

Pilot in vivo evaluation of 10 in four wild-type male C57Bl6/J mice (Figure 3A-C) revealed a favorable pharmacokinetic profile after oral application of 10 mg/kg 10 with rapid uptake, good bioavailability and a terminal half-life of 1.9 h resulting in effective concentrations for PPARγ activation over approx. 4 h. Sufficient concentrations of 10 for sEH inhibition and CysLT1;R antagonism were still detectable after 8 h. The EET/DHET ratio was significantly shifted towards sEH substrates 8 h post dose and of expression PPARγ target gene CD36 was upregulated in mouse livers compared to vehicle treated animals.

<table>
<thead>
<tr>
<th>ID</th>
<th>R1</th>
<th>X</th>
<th>R2</th>
<th>PPARγ EC50 [µM] (max. rel. act. [%])</th>
<th>sEH IC50 [µM]</th>
<th>CysLT1;R pA2</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>C3H6</td>
<td>0</td>
<td>2-CH3</td>
<td>2.44±0.09 (129±4)</td>
<td>2.0±0.3</td>
<td>11.4±0.1</td>
</tr>
<tr>
<td>2</td>
<td>C3H9</td>
<td>NH</td>
<td>2-CH3</td>
<td>2.49±0.09 (21±1)</td>
<td>0.59±0.06</td>
<td>9.1±0.1</td>
</tr>
<tr>
<td>3</td>
<td>C4H11</td>
<td>NH</td>
<td>2-CH3</td>
<td>0.67±0.05 (47±1)</td>
<td>0.15±0.01</td>
<td>7.6±0.1</td>
</tr>
<tr>
<td>4</td>
<td>C4H9</td>
<td>0</td>
<td>H</td>
<td>0.23±0.05 (140±8)</td>
<td>2.5±0.8</td>
<td>10.1±0.1</td>
</tr>
<tr>
<td>5</td>
<td>C3H9</td>
<td>0</td>
<td>3-Cl</td>
<td>0.14±0.01 (73±1)</td>
<td>7±2</td>
<td>10.0±0.1</td>
</tr>
<tr>
<td>6</td>
<td>C4H11</td>
<td>NH</td>
<td>3-Cl</td>
<td>0.37±0.03 (18±1)</td>
<td>0.68±0.06</td>
<td>8.9±0.1</td>
</tr>
<tr>
<td>7</td>
<td>C4H11</td>
<td>NH</td>
<td>3,5-Cl2</td>
<td>0.74±0.03 (29±1)</td>
<td>0.55±0.01</td>
<td>8.2±0.2</td>
</tr>
<tr>
<td>8</td>
<td>C4H11</td>
<td>NH</td>
<td>3-CF3</td>
<td>0.35±0.05 (18±1)</td>
<td>1.49±0.09</td>
<td>8.3±0.1</td>
</tr>
<tr>
<td>9</td>
<td>C4H11</td>
<td>NH</td>
<td>3-F</td>
<td>0.20±0.02 (21±1)</td>
<td>0.41±0.02</td>
<td>7.9±0.1</td>
</tr>
<tr>
<td>10</td>
<td>C4H11</td>
<td>NH</td>
<td>H</td>
<td>0.30±0.02 (36±1)</td>
<td>0.043±0.002</td>
<td>8.7±0.1</td>
</tr>
</tbody>
</table>
Encouraged by the favorable in vitro and pilot in vivo data, we studied anti-inflammatory activity of 10 in the model of paw edema induced by intraplantar injection of zymosan in mice, which closely mimics the symptoms of inflammation in man\(^2\) (Figure 3D). 1 (10 mg/kg), 10 (10 mg/kg) or vehicle were administered orally 30 min prior to zymosan, and the paw edema was assessed by plethysmometry. 8 h after zymosan injection, the paw edema was indistinguishable between groups. 24 h after zymosan injection, the paw edema was significantly reduced in mice treated with 10 compared to vehicle-treated mice whereas 1 did not affect the extent of paw edema. Control experiments revealed no change in paw size in the contralateral hindpaw. These data confirm that 10 exerts anti-inflammatory effects in vivo and that triple target modulation of 10 is superior to 1.

PPAR\(\gamma\) activation\(^,\) e.g. with the full agonist rosiglitazone, as well as sEH inhibition\(^9\) have revealed some therapeutic efficacy in animal models of acute inflammation similar to the paw edema model used in our study. Designing PPAR\(\gamma\) agonistic and sEH inhibitory activity into 1 provided the triple modulator 10 with significantly superior anti-inflammatory effects compared to 1 in a murine model of acute inflammation. Notably, 10 only exhibits partial PPAR\(\gamma\) agonism which proved sufficient to achieve this anti-inflammatory activity underlining a great advantage of multi-target modulation. When supportive target combinations are addressed simultaneously, partial modulation of these targets can be sufficient to achieve the desired therapeutic effects which may allow the development of multi-target compounds with high efficacy and reduced adverse activity\(^2\).

The triple modulatory potency of 10 may be of therapeutic value in a variety of diseases involving inflammatory processes. Particularly, in allergic asthma for which 1 is approved, PPAR\(\gamma\) plays a central role in the regulation of airway inflammation involving modulation of IL-17 production\(^22\) and eosinophil differentiation\(^23\). Moreover, sEH inhibition showed therapeutic efficacy in animal models of allergic asthma including anti-inflammatory and bronchodilatory activity\(^22,24,25\). Even a correlation of PPAR\(\gamma\) polymorphisms with asthma development has been reported\(^26\). Moreover, sEH inhibition reduced allergic airway inflammation and hyperresponsiveness in ovalbumin induced asthma in mice\(^27\) suggesting that all three molecular targets of 10 are suitable to treat allergic asthma.

Beyond asthma, chronic obstructive pulmonary disease (COPD) may also markedly profit from PPAR\(\gamma\) activation combined with inhibition of CysLT\(_1\)R and sEH. Recent clinical observations have found decreased expression of PPAR\(\gamma\) in lung tissue of COPD patients\(^28\) and reduced COPD exacer-

---

**Figure 2.** In vitro pharmacological characterization of triple modulator 10: (A) 10 inhibits sEH product formation with an IC\(_{50}\) value of 14±2 nM in HepG2 cells. (B) Moreover, 10 induces PPAR\(\gamma\) target gene transcription in HepG2 cells. (C/D) However, 10 does not promote adipocyte differentiation (C) or PPAR\(\gamma\) target gene transcription in 3T3-L1 mouse fibroblasts (D). Results are mean±SEM, n=4, * p < 0.05, ** p < 0.01, p < 0.001. CIU - N-cyclohexyl-N-(4-iodophenyl)urea.

**Figure 3.** In vivo pharmacological characterization of triple modulator 10: Pharmacokinetic profiling of 10 after a 10 mg/kg p.o. dose revealed rapid uptake, high bioavailability and a half-life of 2 h (A, results are mean±SEM; n=4). In healthy male wild-type C57BL/6J mice, 10 increased plasma sEH substrate/product ratio (B) and modulated hepatic transcription of PPAR\(\gamma\) target gene CD36 (C, results are mean±SEM; n(vehicle)=2, n(10)=4). In the paw edema model in C57BL/6N mice pretreated with vehicle, 1 or 10 30 min prior to zymosan injection into one hindpaw (D), 10 significantly reduced paw edema after 24 h suggesting anti-inflammatory potency in vivo and was superior to lead compound 1 confirming increased efficacy through designed multi-target activity (solid lines - ipsilateral paw; dotted lines - contralateral paw; results are mean±SEM; n=6). * p < 0.05.
bations in patients receiving PPARγ agonistic thiazolidinediones\textsuperscript{29}. Moreover, treatment with CysLT\textsubscript{1} antagonist \textsuperscript{1} improved the lung function of COPD patients\textsuperscript{36} and sEH inhibitors possessed therapeutic efficacy in COPD mouse models\textsuperscript{31,32}. The rational combination of simultaneously modulating these three biological targets with a single molecule may, therefore, produce superior therapeutic efficacy in COPD.

**CONCLUSION**

The development of triple modulator \textsuperscript{10} and its activity profile compared to \textsuperscript{1} highlight the remarkable impact of very minor structural changes on a drug’s effects and efficacy. Concentrated optimization of intrinsic off-target activities of \textsuperscript{1} generated the potent triple modulator \textsuperscript{10} which by modulating three individual anti-inflammatory targets comprises significantly enhanced anti-inflammatory potency in vivo while conserving the lead compound’s structural properties, molecular weight and pharmacokinetic profile. This alternative interpretation of selective optimization of side-activities\textsuperscript{33} might hold great potential for numerous drug molecules, especially in times of increasing polypharmacy.

**EXPERIMENTAL**

**General.** All final compounds (2-10) for biological evaluation had a purity of >95% according to HPLC-UV analysis at wavelengths 245 and 280 nm.

**Preparation and analytical characterization of triple modulator 10 and intermediates:**

4-\{(5-\{(3-Cyclohexylureido)-1-methyl-1H-indol-3-yl\)-methyl\}-3-methoxy-N-(phenylsulfonyl)benzamide (10): 4-\{(5-\{(3-Cyclohexylureido)-1-methyl-1H-indol-3-yl\)-methyl\}-3-methoxybenzoic acid (24, 50 mg, 0.11 mmol, 1.0 eq) was dissolved in chloroform (abs., 10 mL) and benzenesulfonyl chloride (26.23 mg, 0.15 mmol, 1.30 eq), dicyclohexyl carbodiimide (35 mg, 0.17 mmol, 1.5 eq) and 4-\{(N,N-dimethylaminomethyl)pyridine (14 mg, 0.11 mmol, 1.00 eq) were added and the mixture was stirred under reflux for 12 h. After cooling to room temperature, 10 mL 5% aqueous hydrochloric acid were added, phases were separated, and the aqueous layer was extracted with EtOAc (3x10 mL). The combined organic layers were dried over Na\textsubscript{2}SO\textsubscript{4} and the solvents were evaporated under reduced pressure. The crude product was purified by column chromatography using EtOAc/hexane/acetid acid (9:89:2) as mobile phase. The residue was then dissolved in 0.5 mL methanol, 10 mL water were added, and the suspension was immediately frozen and lyophilized to yield the title compound as colorless solid (50 mg, 76%). \textsuperscript{1}H NMR (400 MHz, CDCl\textsubscript{3}) \(\delta\) = 8.15 (dd, \(j\) = 1.6, 1.6 Hz, 1H), 8.12 (dd, \(j\) = 1.7, 1.7 Hz, 1H), 7.67 – 7.58 (m, 1H), 7.53 (dd, \(j\) = 7.7, 7.7 Hz, 2H), 7.34 (dd, \(j\) = 1.6 Hz, 2H), 7.27 (d, \(j\) = 1.9 Hz, 1H), 7.25 – 7.21 (m, 2H), 7.07 (d, \(j\) = 7.9 Hz, 1H), 7.01 (dd, \(j\) = 8.6, 1.9 Hz, 1H), 6.65 (s, 1H), 4.65 (d, \(j\) = 7.1 Hz, 1H), 4.03 (s, 2H), 3.87 (s, 3H), 3.74 (s, 3H), 1.85 – 1.77 (m, 2H), 1.62 – 1.46 (m, 3H), 1.34 – 1.20 (m, 2H).

**Methyl 4-\{(5-amino-1-methyl-1H-indol-3-yl)methyl\}-3-methoxybenzoate (16):** Methyl 3-methoxy-4-\{(1-methyl-5-nitro-1H-indol-3-yl)methyl\}-benzoate (15, 0.17 g, 0.50 mmol, 1.0 eq) was dissolved in 10 mL EtOH and Pd/C (53 mg, 0.05 mmol, 0.1 eq) was added. The suspension was stirred at room temperature under H\textsubscript{2} atmosphere for 12 h. The mixture was then filtered through celite, the filtrate was dried over MgSO\textsubscript{4} and the solvent was evaporated in vacuum to obtain the title compound as pale purple solid (0.15 g, 94%). \textsuperscript{1}H NMR (250 MHz, DMSO-\textsubscript{d}\textsubscript{6}) \(\delta\) = 7.53 – 7.41 (m, 2H), 7.37 – 7.25 (m, 2H), 7.24 – 7.18 (m, 2H), 7.15 – 7.07 (m, 2H), 7.06 – 6.97 (m, 2H), 6.87 (s, 1H), 6.75 (s, 1H), 4.44 (br s, 2H), 3.95 – 3.87 (m, 5H), 3.83 (s, 3H), 3.62 (s, 3H). MS (ESI+): \(m/z\) 474.32 [M+Na]\textsuperscript{+}.

**Methyl 4-\{(5-(3-cyclohexylureido)-1-methyl-1H-indol-3-yl)methyl\}-3-methoxybenzoate (17):** Methyl 4-\{(5-(3-cyclohexylureido)-1-methyl-1H-indol-3-yl)methyl\}-3-methoxybenzoate (21):
mg, 1.50 mmol, 1.00 eq) was dissolved in THF (abs., 22 mL) and DBU (abs., 0.75 mL) was added. Cyclohexylisocyanate (19, 281 mg, 2.25 mmol, 1.50 eq) was added dropwise and the mixture was stirred at 40°C for 12 h. 30 mL 1% aqueous hydrochloric acid were added and the mixture was stirred for another 5 minutes. After addition of 15 mL EtOAc phases were separated and the aqueous layer was extracted with EtOAc (2x30 mL). The combined organic layers were dried over Na2SO4 and the solvents were evaporated under reduced pressure. The crude product was purified by column chromatography using EtOAc/hexane (1:4) as mobile phase to yield the title compound as colorless solid (330 mg, 49%). 1H NMR (400 MHz, DMSO-d6) δ = 8.03 (s, 1H), 7.50 (d, J = 1.3 Hz, 2H), 7.46 (dd, J = 7.8, 1.5 Hz, 1H), 7.25 (d, J = 8.7 Hz, 1H), 7.14 (d, J = 7.8 Hz, 1H), 7.05 (dd, J = 8.7, 1.9 Hz, 1H), 7.02 (s, 1H), 5.86 (d, J = 7.87 Hz, 1H), 3.96 (s, 2H), 3.93 (s, 3H), 3.84 (s, 3H), 3.69 (s, 3H), 3.53 – 3.39 (m, 1H), 1.85 – 1.76 (m, 2H), 1.71 – 1.62 (m, 2H), 1.59 – 1.50 (m, 1H), 1.38 – 1.07 (m, 5H). MS (ESI+): m/z 450.1 [M+H]^+

ASSOCIATED CONTENT
Supporting Information contains supporting figures, synthetic procedures, analytical characterization and methods for in vitro/in vivo characterization.

Molecular Formula Strings.
This material is available free of charge via the Internet at http://pubs.acs.org.

AUTHOR INFORMATION

Corresponding Author
* Daniel Merk. Phone +49 69 798 29327. E-mail: merk@pharmchem.uni-frankfurt.de

Author Contributions
# S.S. and C.F. contributed equally to first authorship. ## E.P. and D.M. contributed equally to senior authorship. All authors have given approval to the final version of the manuscript.

Notes
The authors declare no competing financial interest.

ACKNOWLEDGMENT

This research was financially supported by the Adolph-Messer-Stiftung. P.H. was supported by the Else-Kroener-Fresenius Stiftung.

ABBREVIATIONS
AIBN, 2,2’-azobis(2-methylpropionitrile); CD36, cluster of differentiation 36; CAR, constitutive androstane receptor; CIU, N-cyclohexyl-N’-(4-iodophenyl)urea; CysLT,R, cysteinyl leukotriene receptor 1; DCC, dicyclohexylcarbodiimide; DHET, dihydroxyeicosatrienoic acid; DIPETA, N,N-diisopropylethylamine; DMAP, 4-(dimethylamino)pyridine; DMS, dimethyl sulfate; DNA, deoxyribonucleic acid; EC50, half maximal effective concentration; EET, epoxygenoicosatrienoic acid; EtOAc, ethyl acetate; HEK293T, human embryonic kidney cells 293T; HepG2, human hepatoma cells; IC50, half maximal inhibitory concentration; LBD, ligand binding domain; NBS, N-bromosuccinimide; PHOME, 3-phenylcyclo-(6-methoxyc-2-naphthenyl)-2-oxoicarboxylic acid methyl ester; PPAR, peroxisome proliferator-activated receptor; PXR, pregnane x receptor; THF, tetrahydrofuran; sEH, soluble epoxide hydrolase; SEM, standard error of the mean.

REFERENCES
(10) Proschan, E.; Heitel, P.; Kalinowski, L.; Merk, D. Opportunities


Table of Contents graphic